Lack of cytoplasmic expression of a new marker programmed cell death ligand-1 in tumor cells is significant

Table 8 The levels of estrogen receptors, progesterone receptors and Ki67 proliferation index according to the breast cancer immune profile

	The combination of the lack of cPDCD1 LG1 in TCs and PDCD1 LG1 IC scores				P value (χ2 test)
	BC with the lack of cPDCD1 LG1 in < 20% of the TCs and PDCD1 LG1 IC scores < 10% (group 1)	BC with the lack of cPDCD1 LG1 in ≥ 20% of the TCs and PDCD1 LG1 IC scores < 10% (group 2)	BC with the lack of cPDCD1 LG1 in < 20% of the TCs and PDCD1 LG1 IC scores ≥ 10% (group 3)	BC with the lack of cPDCD1 LG1 in ≥ 20% of the TCs and PDCD1 LG1 IC scores ≥ 10% (group 4)
Estrogen receptors (%)	89.4 ± 24.91	91.9 ± 25.22	81.4 ± 30.23	42.1 ± 48.94	0.0071,4; 0.0042,4; 0.0053,4
Progesterone receptors (%)	53.4 ± 44.71	53.7 ± 44.32	55.1 ± 40.13	25.4 ± 40.94	0.0411,4; 0.0112,4; 0.0123,4
Ki67 proliferation index (%)	17.2 ± 14.91	29.0 ± 17.82	31.8 ± 27.33	66.2 ± 28.24	0.0141,2; 0.0031,3; < 0.000011,4; 0.000122,4; 0.0033,4

¹Levels of markers in group 1.

²Levels of markers in group 2.

³Levels of markers in group 3.

⁴Levels of markers in group 4.

BC: Breast cancer; cPDCD1 LG1: Cytoplasmic programmed cell death protein 1 ligand 1; ICs: Immune cells; TCs: Tumor cells.